BioLineRX Ltd 2026 Q2 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- BioLineRx reported second quarter 2026 revenues of $0.3 million, primarily from royalties on Airmid Gamida cells product sales of Effects.to.
- Research and development expenses increased to $2.9 million from $2.3 million year over year, mainly due to Glyx one's project expenses.
- General and administrative expenses rose to $0.9 million from $0.2 million, influenced by a prior period reversal of a $0.8 million provision for doubtful accounts.
- Non-operating expenses decreased to $0.7 million from $1.9 million, related to fair value adjustments of warrant liabilities.
- Net loss for Q2 2026 was $4.3 million compared to $3.9 million in Q2 2025.
- Cash and equivalents stood at $13.1 million as of June 30, 2026, sufficient to fund operations into the first half of 2027.
- A $3.75 million registered direct offering was announced and expected to close shortly after the quarter end.
- The phase 1/2 clinical trial of Glyx one in glioblastoma and other high-grade gliomas is progressing well with recruitment on track and dosing in the second cohort underway.
- Preclinical data showed Glyx one’s significant tumor growth inhibition and survival benefits in multiple glioblastoma models, including temozolomide-resistant patient-derived xenografts.
- New preclinical data demonstrated strong synergy between Glyx one and the PARP inhibitor olaparib in HR proficient ovarian cancer models, outperforming monotherapies and comparable to cisplatin chemotherapy.
- Enrollment continues well in the randomized phase 2 trial of motixafortide in pancreatic cancer, with an interim futility analysis planned for later in 2026.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx second quarter 2026 financial results conference call. All participants are presently in a listen-only mode. Following management's formal presentation, instructions will be given for the question and answer session. For operator assistance during the conference, please press star zero. I would now like to turn the call over to Chuck Padala, Investor Relations.
Please go ahead. Thank you, operator, and welcome everyone, and thank you for joining us on our quarterly results conference call.
Earlier today, we issued a press release, a copy of which is available in the investor relations section of our website. It was also filed as a Form 6-K. I'd like to remind everyone that certain statements we make during the call will be forward-looking. Because such statements deal with future events and are subject to many risks and uncertainties, actual results may differ materially from those in the forward-looking statements. For a full discussion of these risks and uncertainties, please review our annual report on Form 20-F and our quarterly reports on Form 6-K that are filed with the U.S. Securities and Exchange Commission. At this time, it is now my pleasure to turn the call over to Mr. Phil Serlin, Chief Executive Officer of BioLineRx.
Thank you, Chuck, and good morning, everyone. Thank you for joining us on today's call. As has been our practice, I will begin with a few prepared remarks before turning the call over to Mali Zeevi, our Chief Financial Officer, to briefly recap our financials. Afterwards, we will take your questions. Ella Sorani, our Chief Development Officer, is also available for Q&A. I'd like to begin this morning with an update on GLIX1, our highly innovative molecule for the treatment of glioblastoma and other cancers, which we obtained through our collaboration with Hemispherian. GLIX1 is an oral first-in-class small molecule with a novel mechanism of action designed to activate the TET2 enzyme and drive tumor DNA damage.
Call participants
6 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring